MedTrace Logo

Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers

NCT07072325 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-08-03

No results posted yet for this study

Summary

The goal of this prospective, single-center, open-label, dose-escalation study is to evaluate the safety, tolerability, and preliminary efficacy of CD-001 in patients with advanced head and neck cancers who have experienced disease progression (PD) or intolerance to standard systemic therapy (or lack thereof). The main question\[s\] it aims to answer:

* What is the safety and tolerability profile of CD-001 across escalating doses?
* What is the preliminary efficacy of CD-001 in this patient population?

Conditions

Interventions

DRUG

CD-001

CD-001 administered as an intravenous (lV)infusion.

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-10
Primary Completion
2027-08-01
Completion
2028-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07072325 on ClinicalTrials.gov